Skip to main content
Top
Published in: Hereditary Cancer in Clinical Practice 1/2013

Open Access 01-12-2013 | Review

Germline deletions in the EPCAM gene as a cause of Lynch syndrome – literature review

Authors: Katarzyna Tutlewska, Jan Lubinski, Grzegorz Kurzawski

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2013

Login to get access

Abstract

Lynch syndrome (clinically referred to as HNPCC – Hereditary Non-Polyposis Colorectal Cancer) is a frequent, autosomal, dominantly-inherited cancer predisposition syndrome caused by various germline alterations that affect DNA mismatch repair genes, mainly MLH1 and MSH2. Patients inheriting this predisposition are susceptible to colorectal, endometrial and other extracolonic tumors. It has recently been shown that germline deletions of the last few exons of the EPCAM gene are involved in the etiology of Lynch syndrome. Such constitutional mutations lead to subsequent epigenetic silencing of a neighbouring gene, here, MSH2, causing Lynch syndrome. Thus, deletions of the last few exons of EPCAM constitute a distinct class of mutations associated with HNPCC. Worldwide, several investigators have reported families with EPCAM 3’end deletions. The risk of colorectal cancer in carriers of EPCAM deletions is comparable to situations when patients are MSH2 mutation carriers, and is associated with high expression levels of EPCAM in colorectal cancer stem cells. A lower risk of endometrial cancer was also reported. Until now the standard diagnostic tests for Lynch syndrome have contained analyses such as immunohistochemistry and tests for microsatellite instability of mismatch repair genes. The identification of EPCAM deletions or larger EPCAM-MSH2 deletions should be included in routine mutation screening, as this has implications for cancer predisposition.
Appendix
Available only for authorised users
Literature
1.
go back to reference Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen J, Lubiński J, Müller H, Ponz De Leon M, Vasen HF, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, Blanco I, Bulow S, Burn J, Capella G, Colas C, Engel C, Frayling I, Rahner N, Hes FJ, Hodgson S, Mecklin JP, Møller P, Myrhøj T, Nagengast FM, Parc Y: Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam Cancer 2010, 9: 109–115. 10.1007/s10689-009-9291-3CrossRefPubMed Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen J, Lubiński J, Müller H, Ponz De Leon M, Vasen HF, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, Blanco I, Bulow S, Burn J, Capella G, Colas C, Engel C, Frayling I, Rahner N, Hes FJ, Hodgson S, Mecklin JP, Møller P, Myrhøj T, Nagengast FM, Parc Y: Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam Cancer 2010, 9: 109–115. 10.1007/s10689-009-9291-3CrossRefPubMed
2.
go back to reference Ligtenberg MJL, Kuiper RP, van Kessel AG, Hoogerbrugge N: EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Fam Cancer 2012. 10.1007/s10689–012–9591-x Ligtenberg MJL, Kuiper RP, van Kessel AG, Hoogerbrugge N: EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Fam Cancer 2012. 10.1007/s10689–012–9591-x
3.
go back to reference Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, Hopper JL, Le Marchand L, Gallinger S, Newcomb PA, Haile R, Thibodeau SN, Gunawardena S, Jenkins MA, Buchanan DD, Potter JD, Baron JA, Ahnen DJ, Moreno V, Andreu M, Ponz De Leon M, Rustgi AK, Castells A: EPICOLON consortium: identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012, 308: 1555–65. 10.1001/jama.2012.13088CrossRefPubMed Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, Hopper JL, Le Marchand L, Gallinger S, Newcomb PA, Haile R, Thibodeau SN, Gunawardena S, Jenkins MA, Buchanan DD, Potter JD, Baron JA, Ahnen DJ, Moreno V, Andreu M, Ponz De Leon M, Rustgi AK, Castells A: EPICOLON consortium: identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012, 308: 1555–65. 10.1001/jama.2012.13088CrossRefPubMed
4.
go back to reference Musulen E, Blanco I, Carrato C, Fernandez-Figueras MT, Pineda M, Capella G, Ariza A: Usefulness of epithelial cell adhesion molecule expression in the algorithmic approach to Lynch syndrome identification. Hum Pathol 2013, 44: 412–6. 10.1016/j.humpath.2012.06.006CrossRefPubMed Musulen E, Blanco I, Carrato C, Fernandez-Figueras MT, Pineda M, Capella G, Ariza A: Usefulness of epithelial cell adhesion molecule expression in the algorithmic approach to Lynch syndrome identification. Hum Pathol 2013, 44: 412–6. 10.1016/j.humpath.2012.06.006CrossRefPubMed
5.
go back to reference Kuiper RP, Vissers LE, Venkatachalam R, Bodmer D, Hoenselaar E, Goossens M, Haufe A, Kamping E, Niessen RC, Hogervorst FB, Gille JJ, Redeker B, Tops CM, van Gijn ME, van den Ouweland AM, Rahner N, Steinke V, Kahl P, Holinski-Feder E, Morak M, Kloor M, Stemmler S, Betz B, Hutter P, Bunyan DJ, Syngal S, Culver JO, Graham T, Ligtenberg MJ: Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat 2011, 32: 407–14. 10.1002/humu.21446CrossRefPubMed Kuiper RP, Vissers LE, Venkatachalam R, Bodmer D, Hoenselaar E, Goossens M, Haufe A, Kamping E, Niessen RC, Hogervorst FB, Gille JJ, Redeker B, Tops CM, van Gijn ME, van den Ouweland AM, Rahner N, Steinke V, Kahl P, Holinski-Feder E, Morak M, Kloor M, Stemmler S, Betz B, Hutter P, Bunyan DJ, Syngal S, Culver JO, Graham T, Ligtenberg MJ: Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat 2011, 32: 407–14. 10.1002/humu.21446CrossRefPubMed
6.
go back to reference Hemminki A, Peltomäki P, Mecklin JP, Järvinen H, Salovaara R, Nyström-Lahti M, de la Chapelle A, Aaltonen LA: Loss of the wild type MLH-1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nature 1994, 8: 405–10. Hemminki A, Peltomäki P, Mecklin JP, Järvinen H, Salovaara R, Nyström-Lahti M, de la Chapelle A, Aaltonen LA: Loss of the wild type MLH-1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nature 1994, 8: 405–10.
7.
go back to reference Huth C, Kloor M, Voigt A, Bozukova G, Evers C, Gaspar H, Tariverdian M, Schirmacher P, Doeberitz M, Bläker H: The molecular basis of EPCAM expression loss in Lynch syndrome-associated tumors. Mod Pathol 2012, 25: 911–6. 10.1038/modpathol.2012.30CrossRefPubMed Huth C, Kloor M, Voigt A, Bozukova G, Evers C, Gaspar H, Tariverdian M, Schirmacher P, Doeberitz M, Bläker H: The molecular basis of EPCAM expression loss in Lynch syndrome-associated tumors. Mod Pathol 2012, 25: 911–6. 10.1038/modpathol.2012.30CrossRefPubMed
8.
go back to reference Peltomäki P, Lothe RA, Aaltonen LA, Pylkkänen L, Nyström-Lahti M, Seruca R, David L, Holm R, Ryberg D, Haugen A: Microsatellite instability is associated with tumors that characterized the hereditary non-polyposis carcinoma syndrome. Cancer Res 1993, 53: 5853–5.PubMed Peltomäki P, Lothe RA, Aaltonen LA, Pylkkänen L, Nyström-Lahti M, Seruca R, David L, Holm R, Ryberg D, Haugen A: Microsatellite instability is associated with tumors that characterized the hereditary non-polyposis carcinoma syndrome. Cancer Res 1993, 53: 5853–5.PubMed
9.
go back to reference Guarinos C, Castillejo A, Barberá VM, Pérez-Carbonell L, Sánchez-Heras AB, Segura A, Guillén-Ponce C, Martínez-Cantó A, Castillejo MI, Egoavil CM, Jover R, Payá A, Alenda C, Soto JL: EPCAM Germ line deletions as causes of Lynch syndrome in Spanish patients. J Mol Diagn 2010, 12: 765–70. 10.2353/jmoldx.2010.100039CrossRefPubMedPubMedCentral Guarinos C, Castillejo A, Barberá VM, Pérez-Carbonell L, Sánchez-Heras AB, Segura A, Guillén-Ponce C, Martínez-Cantó A, Castillejo MI, Egoavil CM, Jover R, Payá A, Alenda C, Soto JL: EPCAM Germ line deletions as causes of Lynch syndrome in Spanish patients. J Mol Diagn 2010, 12: 765–70. 10.2353/jmoldx.2010.100039CrossRefPubMedPubMedCentral
10.
go back to reference Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin JP, Møller P, Myrhoj T, Nagengast FM, Parc Y, Ponz De Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Möslein G: Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013, 62: 812–23. 10.1136/gutjnl-2012-304356CrossRefPubMedPubMedCentral Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin JP, Møller P, Myrhoj T, Nagengast FM, Parc Y, Ponz De Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Möslein G: Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013, 62: 812–23. 10.1136/gutjnl-2012-304356CrossRefPubMedPubMedCentral
11.
go back to reference Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S: Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96: 261–8. 10.1093/jnci/djh034CrossRefPubMedPubMedCentral Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S: Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96: 261–8. 10.1093/jnci/djh034CrossRefPubMedPubMedCentral
13.
go back to reference Nagasaka T, Rhees J, Kloor M, Gebert J, Naomoto Y, Boland CR, Goel A: Somatic hypermethylation of MSH2 is a frequent event in Lynch syndrome colorectal cancers. Cancer Res 2010, 70: 3098–108. 10.1158/0008-5472.CAN-09-3290CrossRefPubMedPubMedCentral Nagasaka T, Rhees J, Kloor M, Gebert J, Naomoto Y, Boland CR, Goel A: Somatic hypermethylation of MSH2 is a frequent event in Lynch syndrome colorectal cancers. Cancer Res 2010, 70: 3098–108. 10.1158/0008-5472.CAN-09-3290CrossRefPubMedPubMedCentral
14.
go back to reference Suter CM, Martin DI: Inherited epimutation or a haplotypic basis for propensity to silence? Nat Genet 2007, 39: 573.CrossRefPubMed Suter CM, Martin DI: Inherited epimutation or a haplotypic basis for propensity to silence? Nat Genet 2007, 39: 573.CrossRefPubMed
15.
go back to reference Hitchins MP, Wong JJ, Suthers G, Suter CM, Martin DI, Hawkins NJ, Ward RL: Inheritance of a cancer-associated MLH1 germ-line epimutation. N Eng J Med 2007, 356: 697–705. 10.1056/NEJMoa064522CrossRef Hitchins MP, Wong JJ, Suthers G, Suter CM, Martin DI, Hawkins NJ, Ward RL: Inheritance of a cancer-associated MLH1 germ-line epimutation. N Eng J Med 2007, 356: 697–705. 10.1056/NEJMoa064522CrossRef
16.
go back to reference Chan TL, Yuen ST, Kong CK, Chan YW, Chan AS, Ng WF, Tsui WY, Lo MW, Tam WY, Li VS, Leung SY: Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet 2006, 38: 1178–83. 10.1038/ng1866CrossRefPubMed Chan TL, Yuen ST, Kong CK, Chan YW, Chan AS, Ng WF, Tsui WY, Lo MW, Tam WY, Li VS, Leung SY: Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet 2006, 38: 1178–83. 10.1038/ng1866CrossRefPubMed
17.
go back to reference Gazzoli I, Loda M, Garber J, Syngal S, Kolodner RD: A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res 2002, 62: 3925–8.PubMed Gazzoli I, Loda M, Garber J, Syngal S, Kolodner RD: A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res 2002, 62: 3925–8.PubMed
18.
go back to reference Kovacs ME, Papp J, Szentirmay Z, Otto S, Olah E: Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat 2009, 30: 197–203. 10.1002/humu.20942CrossRefPubMed Kovacs ME, Papp J, Szentirmay Z, Otto S, Olah E: Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat 2009, 30: 197–203. 10.1002/humu.20942CrossRefPubMed
19.
go back to reference Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, Tsui WY, Kong CK, Brunner HG, van Kessel AG, Yuen ST, van Krieken JH, Leung SY, Hoogerbrugge N: Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3’ exons of TACSTD1 . Nat Genet 2009, 41: 112–7. 10.1038/ng.283CrossRefPubMed Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, Tsui WY, Kong CK, Brunner HG, van Kessel AG, Yuen ST, van Krieken JH, Leung SY, Hoogerbrugge N: Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3’ exons of TACSTD1 . Nat Genet 2009, 41: 112–7. 10.1038/ng.283CrossRefPubMed
20.
go back to reference Kempers MJ, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, Schackert HK, Steinke V, Holinski-Feder E, Morak M, Kloor M, Büttner R, Verwiel ET, van Krieken JH, Nagtegaal ID, Goossens M, van der Post RS, Niessen RC, Sijmons RH, Kluijt I, Hogervorst FB, Leter EM, Gille JJ, Aalfs CM, Redeker EJ, Hes FJ, Tops CM, van Nesselrooij BP, van Gijn ME, Ligtenberg MJ: Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 2011, 12: 49–55. 10.1016/S1470-2045(10)70265-5CrossRefPubMed Kempers MJ, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, Schackert HK, Steinke V, Holinski-Feder E, Morak M, Kloor M, Büttner R, Verwiel ET, van Krieken JH, Nagtegaal ID, Goossens M, van der Post RS, Niessen RC, Sijmons RH, Kluijt I, Hogervorst FB, Leter EM, Gille JJ, Aalfs CM, Redeker EJ, Hes FJ, Tops CM, van Nesselrooij BP, van Gijn ME, Ligtenberg MJ: Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 2011, 12: 49–55. 10.1016/S1470-2045(10)70265-5CrossRefPubMed
21.
go back to reference Pérez-Cabornero L, Infante Sanz M, Velasco Sampedro E, Lastra Aras E, Acedo Becares A, Miner Pino C, Durán Domínguez M: Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5/part of MSH2 . Cancer Prev Res 2011, 4: 1556–62. 10.1158/1940-6207.CAPR-11-0080CrossRef Pérez-Cabornero L, Infante Sanz M, Velasco Sampedro E, Lastra Aras E, Acedo Becares A, Miner Pino C, Durán Domínguez M: Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5/part of MSH2 . Cancer Prev Res 2011, 4: 1556–62. 10.1158/1940-6207.CAPR-11-0080CrossRef
22.
go back to reference Niessen RC, Hofstra RM, Westers H, Ligtenberg MJ, Kooi K, Jager PO, de Groote ML, Dijkhuizen T, Olderode-Berends MJ, Hollema H, Kleibeuker JH, Sijmons RH: Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes cancer 2009, 48: 737–744. 10.1002/gcc.20678CrossRefPubMed Niessen RC, Hofstra RM, Westers H, Ligtenberg MJ, Kooi K, Jager PO, de Groote ML, Dijkhuizen T, Olderode-Berends MJ, Hollema H, Kleibeuker JH, Sijmons RH: Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes cancer 2009, 48: 737–744. 10.1002/gcc.20678CrossRefPubMed
23.
go back to reference Munz M, Baeuerle PA, Gires O: The emerging role of EPCAM in cancer and stem cell signaling. Cancer Res 2009, 69: 5627–9. 10.1158/0008-5472.CAN-09-0654CrossRefPubMed Munz M, Baeuerle PA, Gires O: The emerging role of EPCAM in cancer and stem cell signaling. Cancer Res 2009, 69: 5627–9. 10.1158/0008-5472.CAN-09-0654CrossRefPubMed
24.
go back to reference Sivagnanam M, Schaible T, Szigeti R, Byrd RH, Finegold MJ, Ranganathan S, Gopalakrishna GS, Tatevian N, Kellermayer R: Further evidence for EPCAM as the gene for congenital tufting enteropathy. Am J Med Genet 2010, 152A: 222–4. 10.1002/ajmg.a.33186CrossRefPubMed Sivagnanam M, Schaible T, Szigeti R, Byrd RH, Finegold MJ, Ranganathan S, Gopalakrishna GS, Tatevian N, Kellermayer R: Further evidence for EPCAM as the gene for congenital tufting enteropathy. Am J Med Genet 2010, 152A: 222–4. 10.1002/ajmg.a.33186CrossRefPubMed
25.
go back to reference van der Klift H, Wijnen J, Wagner A, Verkuilen P, Tops C, Otway R, Kohonen-Corish M, Vasen H, Oliani C, Barana D, Moller P, Delozier-Blanchet C, Hutter P, Foulkes W, Lynch H, Burn J, Möslein G, Fodde R: Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6 and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC). Genes Chromosomes Cancer 2005, 44: 123–138. 10.1002/gcc.20219CrossRefPubMed van der Klift H, Wijnen J, Wagner A, Verkuilen P, Tops C, Otway R, Kohonen-Corish M, Vasen H, Oliani C, Barana D, Moller P, Delozier-Blanchet C, Hutter P, Foulkes W, Lynch H, Burn J, Möslein G, Fodde R: Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6 and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC). Genes Chromosomes Cancer 2005, 44: 123–138. 10.1002/gcc.20219CrossRefPubMed
26.
go back to reference Jurka J: Evolutionary impact of human Alu repetitive elements. Curr Opin Genet 2004, 14: 603–8. 10.1016/j.gde.2004.08.008CrossRef Jurka J: Evolutionary impact of human Alu repetitive elements. Curr Opin Genet 2004, 14: 603–8. 10.1016/j.gde.2004.08.008CrossRef
27.
go back to reference Hitchins MP, Burn J: Alu in Lynch syndrome: a danger SINE? Cancer Prev Res 2011, 4: 1527–30. 10.1158/1940-6207.CAPR-11-0417CrossRef Hitchins MP, Burn J: Alu in Lynch syndrome: a danger SINE? Cancer Prev Res 2011, 4: 1527–30. 10.1158/1940-6207.CAPR-11-0417CrossRef
28.
go back to reference Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR: Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis and medicolegal ramifications. Clin Genet 2009, 76: 1–18.CrossRefPubMedPubMedCentral Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR: Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis and medicolegal ramifications. Clin Genet 2009, 76: 1–18.CrossRefPubMedPubMedCentral
29.
go back to reference Grandval P, Baert-Desurmont S, Bonnet F, Bronner M, Buisine MP, Colas C, Noguchi T, North MO, Rey JM, Tinat J, Toulas C, Olschwang S: Colon-specific phenotype in Lynch syndrome associated with EPCAM deletion. Clin Genet 2012, 82: 97–9. 10.1111/j.1399-0004.2011.01826.xCrossRefPubMed Grandval P, Baert-Desurmont S, Bonnet F, Bronner M, Buisine MP, Colas C, Noguchi T, North MO, Rey JM, Tinat J, Toulas C, Olschwang S: Colon-specific phenotype in Lynch syndrome associated with EPCAM deletion. Clin Genet 2012, 82: 97–9. 10.1111/j.1399-0004.2011.01826.xCrossRefPubMed
30.
go back to reference Lynch HT, Riegert-Johnson DL, Snyder C, Lynch JF, Hagenkord J, Boland CR, Rhees J, Thibodeau SN, Boardman LA, Davies J, Kuiper RP, Hoogerbrugge N, Ligtenberg MJ: Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion. Am J Gastroenterol 2011, 106: 1829–1836. 10.1038/ajg.2011.203CrossRefPubMedPubMedCentral Lynch HT, Riegert-Johnson DL, Snyder C, Lynch JF, Hagenkord J, Boland CR, Rhees J, Thibodeau SN, Boardman LA, Davies J, Kuiper RP, Hoogerbrugge N, Ligtenberg MJ: Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion. Am J Gastroenterol 2011, 106: 1829–1836. 10.1038/ajg.2011.203CrossRefPubMedPubMedCentral
31.
go back to reference Pineda M, González S, Lázaro C, Blanco I, Capellá G: Detection of genetic alterations in hereditary colorectal cancer screening. Mutat Res 2010, 693: 19–31. 10.1016/j.mrfmmm.2009.11.002CrossRefPubMed Pineda M, González S, Lázaro C, Blanco I, Capellá G: Detection of genetic alterations in hereditary colorectal cancer screening. Mutat Res 2010, 693: 19–31. 10.1016/j.mrfmmm.2009.11.002CrossRefPubMed
32.
go back to reference Caldés T, Blanco I, Soto J, Capellá G, Lázaro C, Cajal T, Mur P, Pineda M, Romero A, Del Valle J, Borràs E, Canal A, Navarro M, Brunet J, Rueda D, Ramón Y: Identyfication of a founder EPCAM deletion in Spanish Lynch syndrome families. Clin Genet 2013, 2013: 2013. 10.1111/cge.12152 Caldés T, Blanco I, Soto J, Capellá G, Lázaro C, Cajal T, Mur P, Pineda M, Romero A, Del Valle J, Borràs E, Canal A, Navarro M, Brunet J, Rueda D, Ramón Y: Identyfication of a founder EPCAM deletion in Spanish Lynch syndrome families. Clin Genet 2013, 2013: 2013. 10.1111/cge.12152
33.
go back to reference Kloor M, Voigt AY, Schackert HK, Schirmacher P, von Knebel DM, Bläker H: Analysis of EPCAM protein expression in diagnostics of Lynch syndrome. J Clin Oncol 2011, 29: 223–7. 10.1200/JCO.2010.32.0820CrossRefPubMed Kloor M, Voigt AY, Schackert HK, Schirmacher P, von Knebel DM, Bläker H: Analysis of EPCAM protein expression in diagnostics of Lynch syndrome. J Clin Oncol 2011, 29: 223–7. 10.1200/JCO.2010.32.0820CrossRefPubMed
34.
go back to reference Pritchard CC, Smith C, Salipante SJ, Lee MK, Thornton AM, Nord AS, Gulden C, Kupfer SS, Swisher EM, Bennett RL, Novetsky AP, Jarvik GP, Olopade OI, Goodfellow PJ, King MC, Tait JF, Walsh T: ColoSeq provides comprehensive Lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012, 14: 357–66. 10.1016/j.jmoldx.2012.03.002CrossRefPubMedPubMedCentral Pritchard CC, Smith C, Salipante SJ, Lee MK, Thornton AM, Nord AS, Gulden C, Kupfer SS, Swisher EM, Bennett RL, Novetsky AP, Jarvik GP, Olopade OI, Goodfellow PJ, King MC, Tait JF, Walsh T: ColoSeq provides comprehensive Lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012, 14: 357–66. 10.1016/j.jmoldx.2012.03.002CrossRefPubMedPubMedCentral
Metadata
Title
Germline deletions in the EPCAM gene as a cause of Lynch syndrome – literature review
Authors
Katarzyna Tutlewska
Jan Lubinski
Grzegorz Kurzawski
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 1/2013
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/1897-4287-11-9

Other articles of this Issue 1/2013

Hereditary Cancer in Clinical Practice 1/2013 Go to the issue

Letter to the Editor

Carcinogenesis of PIK3CA

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine